Fortrea Holdings (FTRE) EBITDA Margin (2022 - 2026)
Fortrea Holdings' (FTRE) quarterly EBITDA Margin came in at 2.18% in Q2 2026, up 4868.0% on a YoY basis from 0.04% in Q2 2025, and up 508.53% quarter-over-quarter from 0.53% in Q1 2026.
Analysis
Fortrea Holdings (FTRE) EBITDA Margin (2022 - 2026) Analysis & Trends
Fortrea Holdings (FTRE) has reported EBITDA Margin for 5 consecutive years, with 2.18% the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, EBITDA Margin rose 4868.0% year-over-year to 2.18%; the trailing twelve-month figure through Jun 2026 stood at 0.4% (up 3340.0% YoY), and the FY2025 full-year result was 31.32%, down 2622.0% from the prior year.
- EBITDA Margin grew to 2.18% in Q2 2026 per FTRE's latest filing, from 0.53% in the prior quarter.
- Across five years, EBITDA Margin topped out at 9.04% in Q3 2022 and bottomed at 79.86% in Q1 2025.
- Historically, EBITDA Margin has averaged 7.45% across 5 years, with a median of 1.23% in 2025.
- The sharpest annual moves came in 2025 and 2026: EBITDA Margin plunged 7421 bps in 2025, then jumped 7932 bps in 2026.
- Over 5 years, EBITDA Margin stood at 2.85% in 2022, then sank by 219 bps to 3.38% in 2023, then sank by 136 bps to 7.98% in 2024, then soared by 74 bps to 2.06% in 2025, then surged by 206 bps to 2.18% in 2026.
- According to Business Quant data, EBITDA Margin over the past three periods registered 2.18%, 0.53%, and 2.06% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Iqvia Holdings | 42.77 Bn | 40.69 Bn | 1.44 Bn | 11.58% |
| 2 | Medpace Holdings | 16.50 Bn | 16.00 Bn | 201.64 Mn | 21.68% |
| 3 | Charles River Laboratories International | 13.37 Bn | 13.18 Bn | 452.07 Mn | 11.94% |
| 4 | Icon | 12.49 Bn | 11.56 Bn | 479.29 Mn | 15.86% |
| 5 | Fortrea Holdings | 1.58 Bn | 1.42 Bn | 139.20 Mn | 2.18% |
| 6 | Evotec SE | 642.83 Mn | 216.96 Mn | - | - |
| 7 | Ginkgo Bioworks Holdings | 422.55 Mn | 338.02 Mn | 18.44 Mn | -290.47% |
| 8 | Champions Oncology | 69.16 Mn | 69.16 Mn | 7.03 Mn | -3.77% |
| 9 | MindWalk Holdings | 59.83 Mn | 51.55 Mn | 1.82 Mn | -77.57% |
| 10 | VivoSim Labs | 1.45 Mn | 1.45 Mn | - | -15,327.78% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.18% |
| Mar 31, 2026 | -0.53% |
| Dec 31, 2025 | -2.06% |
| Sep 30, 2025 | -1.23% |
| Jun 30, 2025 | -46.50% |
| Mar 31, 2025 | -79.86% |
| Dec 31, 2024 | -7.98% |
| Sep 30, 2024 | -2.67% |
| Jun 30, 2024 | -7.68% |
| Mar 31, 2024 | -5.65% |
| Dec 31, 2023 | -3.38% |
| Sep 30, 2023 | 1.44% |
| Jun 30, 2023 | 4.36% |
| Mar 31, 2023 | 2.03% |
| Dec 31, 2022 | 2.85% |
| Sep 30, 2022 | 9.04% |
| Jun 30, 2022 | 8.98% |